Lilly(Eli) & Co
Lilly(Eli) & Co (LLY) Covered Calls
As of September 25, 2026, LLY has 657 covered call opportunities in the coming three months. Return ranges from 1.8 to 70.5% until expiration. Annualized return ranges from 11.7 to 866.2%. The nearest expiration is October 2, 2026. Maximum potential profit is $83,454.
Read more
Running LLY covered calls helps you generate consistent income from Lilly(Eli) & Co's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Lilly(Eli) & Co involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best LLY covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if LLY stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling LLY covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Lilly(Eli) & Co covered call is worth writing.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer.
It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Income-focused investors, long-term LLY holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling LLY covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Lilly(Eli) & Co covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryDrug Manufacturers - General
- SectorHealthcare
- IV percentile64.29% Neutral
- Market cap (M$)1,114,058
- 52 weeks high-8.45%
- 52 weeks low65.27%
- Analyst recommendationStrong Buy
1.50 - Target price$1,359.46
14.04% above the current stock price - Dividend—
- Payout ratio26.14%
- Earnings date2026-10-29
- P/E40.21
- Future P/E25.22
- EPS (ttm)29.43
- EPS growth next 5 years30.55%
As of September 25, 2026
| 2026-10-02 | 7 | 1380.00 | 16.61 | 0.05 | 0.50 | 19659.00 | 16.61 | 866.17 | -0.00 | +0.01 | 56 | 0.45 |
| 2026-10-02 | 7 | 1360.00 | 14.92 | 0.05 | 0.50 | 17659.00 | 14.92 | 778.05 | -0.00 | +0.01 | 63 | 0.45 |
| 2026-10-09 | 14 | 1500.00 | 26.75 | 0.05 | 0.29 | 31659.00 | 26.75 | 697.44 | -0.00 | +0.01 | 2 | 0.24 |
| 2026-10-02 | 7 | 1325.00 | 11.96 | 0.07 | 0.35 | 14161.00 | 11.97 | 623.93 | -0.01 | +0.01 | 52 | 0.28 |
| 2026-10-09 | 14 | 1460.00 | 23.37 | 0.01 | 0.87 | 27655.00 | 23.37 | 609.24 | -0.00 | +0.01 | 4 | 0.86 |
| 2026-10-16 | 21 | 1580.00 | 33.51 | 0.04 | 0.55 | 39658.00 | 33.51 | 582.44 | -0.00 | +0.01 | 73 | 0.51 |
| 2026-10-02 | 7 | 1315.00 | 11.11 | 0.01 | 1.29 | 13155.00 | 11.12 | 579.60 | -0.00 | +0.03 | 72 | 1.28 |
| 2026-10-02 | 7 | 1305.00 | 10.27 | 0.02 | 0.55 | 12156.00 | 10.27 | 535.59 | -0.00 | +0.02 | 58 | 0.53 |
| 2026-10-16 | 21 | 1540.00 | 30.13 | 0.04 | 0.37 | 35658.00 | 30.13 | 523.69 | -0.00 | +0.01 | 79 | 0.33 |
| 2026-10-09 | 14 | 1420.00 | 19.99 | 0.01 | 0.71 | 23655.00 | 19.99 | 521.12 | -0.00 | +0.01 | 15 | 0.70 |
As of September 25, 2026
Sell covered calls with the data behind you
Find the best LLY covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→